Natural products as source of potential dengue antivirals

Molecules

Volumn 19, Issue 6, 2014, Pages 8151-8176

  Teixeira, Róbson Ricardo ^a   Pereira, Wagner Luiz ^a   Da Silveira Oliveira, Ana Flávia Costa ^a,b   Da Silva, Adalberto Manoel ^a   De Oliveira, André Silva ^a,b   Da Silva, Milene Lopes ^a   Da Silva, Cynthia Cânedo ^a   De Paula, Sérgio Oliveira ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b Departamento de Produção   (Brazil)

Author keywords

Antiviral natural products; Dengue fever; Dengue virus

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL PRODUCT;

CHEMISTRY; DENGUE VIRUS; DRUG EFFECTS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; DENGUE VIRUS; VIRUS REPLICATION;

EID: 84903280955     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19068151     Document Type: Review

References (69)

1. Kroe ger A. Nathan M.B. Dengue: Setting the global research agenda Lancet 2006 368 2193-2195.
2. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health social and economic problem in the 21st century. Trends Microbiol. 2002 10 100-103.
3. Normile D. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013 342 415.
4. Gubler D.J.; Clark G.G. Dengue/dengue hemorrhagic fever: The emergence of a global health problem. Emerg. Infect. Dis. 1995 1 55-57.
5. Chambers T.J.; Hahn C.S.; Galler R.; Rice C.M. Flavivirus genome organization expression and replication. Annu. Rev. Microbiol. 1990 44 649-688.
6. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 1998 11 480-496.
7. Wright P.F.; Durbin A.P.; Whitehead S.S.; Ikizler M.R.; Henderson S.; Blaney J.E.; Thumar B.; Ankrah S.; Rock M.T.; McKinney B.A.; et al. Phase 1 trial of the dengue virus t ype 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am. J. Trop. Med. Hyg. 2009 81 834-841.
8. Messina J.P.; Brady O.J.; Scott T.W.; Zou C.; Pigott D.M.; Duda K.A.; Bhatt S.; Katzelnick L.; Howes R.E.; Battle K.E.; et al. Global Spread of virus types: Mapping the 70 year history. Trends Microbiol. 2014 22 138-146.
9. World Health Organization (W HO). Dengue: Guidelines for Diagnosis Treatment Prevention and Control; WHO: Geneva Switzerland 2009; pp. 25-58.
10. Simmons C.P.; Farrar J.J.; Nguyen V.V.; Wills B. Dengue. N. Eng. J. Med. 2012 366 1423-1432.
11. Maves R.C.; Ore R.M.; Porter K.R.; Kochel T.J. Immunogenicity andprotective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotusnancymaae monkeys. Vaccin e 2011 29 2691-2696.
12. Tassniyom S.; Vasanawathana S.; Chirawatkul A.; Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: A placebo-controlled double-blind study. Pediatrics 1993 92 111-115.
13. Beatty M.E.; Beutels P.; Meltzer M.I.; Shepard D.S.; Hombach J.; Hutubessy R.; Dessis D.; Coudeville L.; Dervaux B.; Wichmann O.; et al. Health economics of dengue: A systematic literature review and expert panel's assessment. Am. J. Trop. Med. Hyg. 2011 84 473-488.
14. Lim S.P.; Wang Q.Y.; Noble C.G.; Chen Y.L.; Dong H.; Zou B.; Yokokawa F.; Nilar S.; Smith P.; Beer D.; et al. Ten years of dengue drug discovery: Progress and prospects. Antivir. Res. 2013 100 500-519.
15. Tomlinson S.M.; Malmstrom R.D.; Watowich S.J. New approaches to structure-based discovery of dengue protease inhibitors. Infect. Disord. Drug Targets 2009 9 327-343.
16. Phillipson D.J. Phytochemistry and medicinal plants. Phytochemistry 2001 56 237-243.
17. Butler M.S. T he role of natural product chemistry in drug discovery. J. Nat. Prod. 2004 67 2141-2153.
18. Koehn F.E.; Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005 4 206-220.
19. Newman D.J.; Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007 70 461-477.
20. Baker D.D.; Chu M. ; Oza U.; Rajgarhia V. The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep. 2007 24 1225-1244.
21. Newman D.J.; Cragg G.M. Natural Products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012 75 311-355.
22. Cordell G.A. Colvard M.D Natural products and traditional medicine: Turning on a paradigm. J. Nat. Prod. 2012 75 514-525.
23. Dos Santos N.P.; Pinto A.C. The forest is his pharmacy-The research of Brazilian plants to combat tropical diseases in the nineteenth century. Rev. Virtual Quim. 2012 4 162-172.
24. Kadir S.L.A.; Yakoob H.; Zulkifli R.M. Potential anti-dengue medicinal plants: A review. J. Nat. Med. 2013 67 677-689.
25. World Health Organization. Traditional medicine. Available online: http://www.who.int/mediacentre/factsheets/2003/fs134/en/(accessed on 2 February 2014).
26. Betancur-Galvis L.A.; Saez J.; Granados H.; Slazar A.; Ossa J.E. Antitumor and antiviral activity of Colombian medicinal plant extracts. Mem. Inst. Oswaldo. Cruz 1999 94 531-535.
27. Kudi A.C.; Myint S.H. Antiviral activity of some Nigerian medicinal plants extracts. J. Ethnopharmacol. 1999 68 289-294.
28. Li Bo; Lu F.; Wei X.; Zhao R. Fucoidan: Structure and bioactivity. Molecules 2008 13 1671-1695.
29. Hidari K.I.P.J.; Abe T.; Suzuki T. Carbohydrate-related inhibitors of dengue virus entry. Viruses 2013 5 605-618.
30. Fitton J.H. Therapies from fucoidan; multifunctional marine polymers. Mar. Drugs 2011 9 1731-1760.
31. Hidari K.I.P.J.; Takahashi N.; Arihara M.; Nagaoka M.; Morita K.; Suzuki T. Structure and anti-dengue virus activity of sulfate polysaccharide from a marine alga. Biochem. Biophys. Res. Commun. 2008 376 91-95.
32. Marks R.M.; Lu H.; Sundaresan R.; Toida T.; Suzuki A.; Imanari T.; Hernáiz M.J.; Linhardt R.J. Probing the interaction of dengue virus envelope protein with heparin: Assessment of glycosaminoglycan-derived inhibitors. J. Med. Chem. 2001 44 2178-2187.
33. Estevez J.M.; Ciancia M.; Cerezo A.S. DL-Galactan hybrids and agarans from gametophytes of the red seaweed Gymnogongrus. torulosus. Carb. Res. 2001 331 27-41.
34. Talarico L.B.; Zibetti R.G.M.; Faria P.C.S.; Scolaro L.A.; Duarte M.E.R.; Noseda M.D.; Pujol C.A.; Damonte E.B. Anti-her pes simplex virus activity of sulfated galactans from the red seaweeds Gymnogongrus. griffithsiae and Cryptonemia. crenulata. Int. J. Biol. Biol. Macromol. 2004 34 63-71.
35. Paint T.J. The Polysaccharides; As pinall G.O. Ed.; Academica Press: New York NY USA 1983; Volume 2 pp. 195-285.
36. Kraan S. Algal Polysaccharides Novel Applications and Outlook; In Tech: Rijeka Croatia 2012; pp. 489-532.
37. Jiao G.; Yu G.; Zhang J.; Ewart H.S. Chemical structures and bioactivities of sulfated polysaccharides from marine algae. Mar. Drugs 2011 9 196-223.
38. T alarico L.B.; Damonte E.B. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007 363 473-485.
39. Talarico L.B.; Pujol C.A.; Zibetti R.G.M.; Faría P.C.S .; Noseda M.D.; Duarte M.E.R.; Damonte E.B. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antivir. Res. 2005 66 103-110.
40. Tischer P.C.S.F.; Talarico L.B.; Noseda M.D.; Guimara es S.M.P.B.; Damonte E.B.; Duarte M.E.R. Chemical structure and antiviral activity of carrageenans from Meristiella gelidium against herpes simplex and dengue virus. Carbohyd. Polym. 2006 63 459-465.
41. Pujol C.A.; Estevez J.M.; Carlucci M.J.; Ciancia M.; Cerezo A.S.; Damonte E.B. Novel DL-galactan hybrids from the red seaweed Gymnog ongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir. Chem. Chemoth. 2002 13 83-89.
42. Liang W.; Mao X.; Peng X.; Tang S. Effects of sulfate group in red seaweed polysaccharides on anticoagulant and cytotoxicity. Carbohydr. Polym. 2014 101 776-785.
43. Srivastava M. Kapoor V.P Seed galactomannas: An overview. Chem. Biodivers. 2005 2 295-317.
44. Secouard S.; Grisel M.; Malhiac C. Flavour release study as a way to explain xanthangalactomannan interactions. Food Hydrocolloid. 2007 21 1237-1244.
45. Ono L.; Wollinger W.; Rocco I.M.; Coimbra T.L.M.; Gorin P.A.J.; Sierakowski M.-R. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Ant iviral Res. 2003 60 201-208.
46. Sá nchez I.; Garibay F.G.; Taboada J.; Ruiz B.H. Antiviral effect of flavonoids on the dengue virus. Phytother. Res. 2000 14 89-92.
47. Leardkamolkarn V.; Sirigulpanit W.; Phurimsak C.; Kumkate S.; Himakoun L.; Sripanidkulchai B. The inhibitory actions of Houttuynia cordata aqueous extract on dengue virus and dengue-infected cells. J. Food Biochem. 2012 36 86-92.
48. Kiat T.S.; Pippen R.; Yusof R.; Ibrahim H.; Khalid N.; Rahman N.A. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerrot Boesenbergia rotunda (L.) towards dengue-2 virus NS3 protease. Bioorg. Med. Chem. Lett. 2006 16 3337-3340.
49. Zandi K.; Teoh B.T.; Sam S.S.; Wong P.F.; Mustafa M.R.; Abubakar S. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virol. J. 2011 8 1-11.
50. Zandi K.; Teoh B.T.; Sam S.S.; Wong P.F.; Mustafa M.R.; AbuBakar S. I n vitro antiviral activity of fisetin rutin and naringenin against Dengue virus type-2. J. Med. Plants Res. 2011 5 5534-5539.
51. Allard P.M.; Dau E.T.H.; Eydoux C.; Guillemot J.C.; Dumontet V.; Poullain C.; Canard B.; Gué rrite F.; Litaudon M. Alkylated flavanones from the bark of Cryptocarya. chartacea as dengue virus NS5 polymerase inhibitors. J. Nat. Prod. 2011 11 2446-2453.
52. Zandi K.; Teoh B.T.; Sam S.S.; Wong P.F.; Mustafa M.R.; AbuBakar S. Novel antiviral activity of baicalein agains dengue virus. BMC Complement. Altern. Med. 2012 12 1-9.
53. Simoes L.R.; Maciel G.M.; Branda o G.C.; Kroon E.G.; Castilho R.O.; Oliveira A.B. Antiviral activity of Distictella. elongate (Vahl) Urb. (Bignoniaceae) a potentially useful source of antidengue drugs from the state of Minas G erais Brazil. Lett. Appl. Microbiol. 2011 53 602-607.
54. Low J.S.Y.; Chen K.C.; Wu K.X.; Ng M.M.L.; Chu J.J.H. Antiviral activity of emetine dihydrochloride against dengue virus infection. J. Antivir. Antiretrovir. 2009 1 062-071.
55. Jia F.; Zou G.; Fan J.; Yuan Z. Identification of palmatine as an inhibitor of West Nile virus. Arch. Virol. 2010 155 1325-1329.
56. Whitby K.; Pierson T.C.; Geiss B.; Lane K.; Engle M.; Zhou Y.; Doms R.W.; Diamond M.S. Castanospermine a p otent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 2005 79 8698-8706.
57. Zhang X.G.; Mason P.W.; Dubovi E.J.; Xu X.; Bourne N.; Renshaw R.W.; Block T.M.; Birk A.V. Antiviral activity of geneticin against dengue virus. Antivir. Res. 2009 83 21-27.
58. Allard P.M.; Leyssen P.; Martin M.T.; Bourjot M.; Dumontet V.; Eydoux C.; Guillemot J.C.; Canard B.; Poullain C.; Gué rrite F. Antiviral chlorinated daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri. Phytochemistry 2012 84 160-168.
59. Brandao G.C.; Kroon E.G.; Souza D.E.R.; Filho J.D.S.; Oliveira A.B. Chemistry and antiviral activity of Arrabidaea pulchra (Bignoniaceae). Molecules 2013 18 9919-9932.
60. Hamann M. ; Donia M. Marine natural products and their potential applications as anti-infective agents. Lancet 2003 3 338-348.
61. Laille M.; Gerald F.; Debitus C. In vitro antiviral activity on dengue virus of marine natural products. Cell. Mol. Life Sci. 1998 54 167-170.
62. Laurent D.; Baumann F.; Benoit A.G.; Mortelecqe A.; Nitatpattana N.; Desvignes I.; Debitus C.; L aille M.; Gonzales J.P.; Chungue E. Structure-activity relationships of dengue antiviral polycyclic quinones. Southeast. Asian J. Trop. Med. Public Health 2005 36 901-905.
63. Bourjot M.; Leysse n P.; Eydoux C.; Guillemot J.C.; Canard B.; Rasoanaivo P.; Gué rrite F.; Litaudon M. Flacourtosides A.F.phenolic glycosides isolated from Flacourtia. ramontchi. J. Nat. Prod. 2012 75 752-758.
64. Rahman N.A.; Hadinur B.; Muliawan S.; Rashid N.N.; Muhamad M.; Yusof R. Studies on Quercus. lusitanic extracts on DENV-2 replication. Deng. Bull. 2006 30 260-269.
65. Rees C.R. Costin J.M. Fink R.C. McMichael M. Fontaine K.A. Isern S. Michael S.F Vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries. Antivir. Re s. 2008 80 135-142.
66. Zasloff M.; Adams A.P.; Beckerman B.; Campbell A.; Han Z.; Luijten E.; Meza I.; Julander J.; Mishra A.; Qu W.; et al. Squalamine as a bro ad-spectrum systemic antiviral agent with therapeutic potential. Proc. Natl. Acad. Sci. USA 2011 108 15978-15983.
67. Crance J.M.; Scaramozzino N.; Jouan A.; Garin D. Interferon ribavirin 6-A zauridine and glycyrrhizin: Antiviral compounds active against pathogenic flaviviruses. Antivir. Res. 2003 58 73-79.
68. Low J.S.Y.; Wu K.X.; Chen K.C.; Ng M.M.L.; Chu J.J.H. Narasin a novel antiviral compound that blocks dengue virus protein expression. Antivir. Ther. 2011 16 1203-1218.
69. Bourjo t M.; Leyssen P.; Eydoux C.; Guillemot J.C.; Canard B.; Rasoanaivo P.; Gué rrite F.; Litaudon M. Chemical constituents of Anacolosa. pervilleana and their antiviral activities. Fitoterapia 2012 83 1076-1080.